William L Redmond

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 20

Top Venues

Journal for immunotherapy of cancer

Cancer immunology research

Molecular cancer research : MCR

Immunological investigations

Earle A. Chiles Research Institute

Scripps Research Institute (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Earle A. Chiles Research Institute Oct 01 2015

United States

Associate Member :: Cancer Research

Earle A Chiles Research Institute Sep 01 2009 - Oct 01 2015

United States

Assistant Member :: Cancer Research

Education History

Scripps Research Institute Aug 01 1999 - Sep 30 2004

United States

PHD :: Immunology

Publications

David B Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L Redmond, Maritza Martel, Zhaoyu Sun, Mary B Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Dorothy Park, Laura Bennetts, Robert S Seitz, Tyler J Nielsen, Kimberly McGregor, Venkatesh Rajamanickam, Brady Bernard, Walter J Urba, Heather L McArthur
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer. NPJ breast cancer 9 (1) (2023)
Daniel C Rose, Annah S Rolig, William L Redmond
Characterization of murine lymphocyte activation and exhaustion markers by a 14-color flow cytometry panel. Bioanalysis (2023)
Mia Han, Bianca Nguyen, Jack Y Lee, Erica Browning, Jun Zhang, Anandaroop Mukhopadhyay, Ravindra Gujar, Jon Salazar, Reneta Hermiz, Lauren Svenson, Annah S Rolig, William L Redmond, Alain Patrick Algazi, Adil I Daud, David A Canton, Christopher G Twitty
Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity. Molecular cancer research : MCR 20 (6) (2022)
Brie Chun, Joanna Pucilowska, ShuChing Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul A Fields, Valerie Conrad, Mark Schmidt, Walter J Urba, Alison K Conlin, Heather L McArthur, David B Page
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer. Journal for immunotherapy of cancer 10 (1) (2022)
Rashi Yadav, William L Redmond
Current Clinical Trial Landscape of OX40 Agonists. Current oncology reports 24 (7) (2022)
Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brendan D Curti, Walter J Urba, Brian D Piening, William L Redmond
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab. Journal for immunotherapy of cancer 9 (10) (2022)
Annah S Rolig, Daniel C Rose, Grace Helen McGee, Werner Rubas, Saul Kivimäe, William L Redmond
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8 + T cell cytotoxicity over BEMPEG+RT. Journal for immunotherapy of cancer 10 (4) (2022)
Yoshinobu Koguchi, William L Redmond
A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood. Immunological investigations (2022)
Julie N Graff, Tomasz M Beer, Joshi J Alumkal, Rachel E Slottke, William L Redmond, George V Thomas, Reid F Thompson, Mary A Wood, Yoshinobu Koguchi, Yiyi Chen, Emile Latour, Raymond C Bergan, Charles G Drake, Amy E Moran
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. Journal for immunotherapy of cancer 8 (2) (2021)
Zhaoyu Sun, Richard Nyberg, Yaping Wu, Brady Bernard, William L Redmond
Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers. PloS one 16 (2) (2021)
Joshua M Walker, Annah S Rolig, Deborah H Charych, Ute Hoch, Melissa J Kasiewicz, Daniel C Rose, Michael J McNamara, Ian F Hilgart-Martiszus, William L Redmond
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer. Journal for immunotherapy of cancer 8 (1) (2021)
Elizabeth R Sturgill, Annah S Rolig, Stefanie N Linch, Courtney Mick, Melissa J Kasiewicz, Zhaoyu Sun, Peter G Traber, Harold Shlevin, William L Redmond
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. Oncoimmunology 10 (1) (2021)
Dana A Emerson, Annah S Rolig, William L Redmond
Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4-Targeted Immunotherapy. Cancer immunology research 9 (4) (2021)
Brendan D Curti, Yoshinobu Koguchi, Rom S Leidner, Annah S Rolig, Elizabeth R Sturgill, Zhaoyu Sun, Yaping Wu, Venkatesh Rajamanickam, Brady Bernard, Ian Hilgart-Martiszus, Christopher B Fountain, George Morris, Noriko Iwamoto, Takashi Shimada, ShuChing Chang, Peter G Traber, Eliezer Zomer, J Rex Horton, Harold Shlevin, William L Redmond
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. Journal for immunotherapy of cancer 9 (4) (2021)
Mark D Badeaux, Annah S Rolig, Giulia Agnello, Danlee Enzler, Melissa J Kasiewicz, Leslie Priddy, Jason F Wiggins, Alexander Muir, Mark R Sullivan, Jessica Van Cleef, Christopher Daige, Matthew G Vander Heiden, Venkatesh Rajamanickam, James E Wooldridge, William L Redmond, Scott W Rowlinson
Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth. Cancer immunology research 9 (4) (2021)
Mohammad Farhad Amani, Annah S Rolig, William L Redmond
Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8+ T Cell Development. Journal of immunology (Baltimore, Md. : 1950) 205 (7) (2020)
David B Page, Joanna Pucilowska, Katherine G Sanchez, Valerie K Conrad, Alison K Conlin, Anupama K Acheson, Kelly S Perlewitz, James H Imatani, Shaghayegh Aliabadi-Wahle, Nicole Moxon, Staci L Mellinger, Amanda Y Seino, Martiza Martel, Yaping Wu, Zhaoyu Sun, William L Redmond, Venkatesh Rajamanickam, Dottie Waddell, Deborah Laxague, Monil Shah, Shu-Ching Chang, Walter J Urba
A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (7) (2019)
Dana A Emerson, William L Redmond
Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 32 (3) (2018)
Valerie K Conrad, Christopher J Dubay, Mehrnoush Malek, Ryan R Brinkman, Yoshinobu Koguchi, William L Redmond
Implementation and Validation of an Automated Flow Cytometry Analysis Pipeline for Human Immune Profiling. Cytometry. Part A : the journal of the International Society for Analytical Cytology 95 (2) (2018)
Stefanie N Linch, Melissa J Kasiewicz, Michael J McNamara, Ian F Hilgart-Martiszus, Mohammad Farhad, William L Redmond
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Proceedings of the National Academy of Sciences of the United States of America 113 (3) (2016)

William L Redmond.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

William L Redmond